Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (Neo-DREAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03567889
Recruitment Status : Recruiting
First Posted : June 26, 2018
Last Update Posted : September 18, 2020
Sponsor:
Information provided by (Responsible Party):
Philogen S.p.A.

Brief Summary:
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Condition or disease Intervention/treatment Phase
Melanoma Stage IIIB/C Drug: Daromun Procedure: Surgery Drug: Adjuvant therapy Phase 3

Detailed Description:

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of Daromun neoadjuvant intratumoral treatment followed by surgery and adjuvant therapy versus surgery and adjuvant therapy in clinical stage III B/C melanoma patients. 186 patients will be randomized in a 1:1 ratio to receive Daromun treatment followed by surgery and adjuvant therapy (Arm 1) or surgery and adjuvant therapy (Arm 2).

In both arms, follow-up for assessing recurrence-free survival will be performed up to five years after randomization. Survival information will also be collected in the following year (up to six years in total after randomization).

This is an open-label study, so there is no blinding.

Patients who successfully complete the screening evaluations and are eligible for participation in the study will be enrolled and randomly assigned (1:1) to two parallel treatment arms: Daromun plus surgery and adjuvant therapy (Arm 1) or surgery and adjuvant therapy (Arm 2).

To ensure a balance across treatment groups, stratified randomization with permuted block will be used and separate randomization list for each subgroup (stratum) will be produced. Patients will be stratified on the basis of the following prognostic factors:

  • Stage of disease (2 levels): Stage IIIB vs. Stage IIIC
  • Planned post-surgical adjuvant therapy (2 levels): anti-PD-1 and other adjuvant therapies.

The primary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Primary endpoint of the study is RFS in a time-to-event analysis in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus the surgery plus adjuvant therapy control group (Arm 2). Analysis will be based on the "Intention To Treat" population.

The key secondary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant manner the overall survival (OS) of patients with resectable Stage IIIB/ or C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

For patients enrolled in both arms, FDA-approved post-surgery adjuvant therapies (as part of the standard of care) are allowed and decided at the investigator's discretion. These include high-dose interferon- α2b, anti-CTLA-4 antibodies (e.g. Ipilimumab), anti-PD1 antibodies (e.g. Nivolumab, Pembrolizumab), targeted therapies (e.g. Dabrafenib + Trametinib), or other new FDA-approved treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Total patients: approximately 186. Daromun plus surgery and adjuvant therapy treatment group (Arm 1): 93evaluable patients. Surgery and adjuvant therapy (Arm 2): 93 evaluable patients. Patients enrolled will be randomized to the two different arms of the study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Actual Study Start Date : September 20, 2018
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Daromun plus Surgery and Adjuvant therapy (Arm 1)
Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
Drug: Daromun
Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.

Procedure: Surgery
Patients in Arm 2 will receive surgery within 4 weeks from randomisation.

Drug: Adjuvant therapy
Patients will receive adjuvant therapy at the investigator's discretion following the surgery.

Active Comparator: Surgery and adjuvant therapy (Arm 2)
Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
Procedure: Surgery
Patients in Arm 2 will receive surgery within 4 weeks from randomisation.

Drug: Adjuvant therapy
Patients will receive adjuvant therapy at the investigator's discretion following the surgery.




Primary Outcome Measures :
  1. Recurrence Free Survival (RFS) [ Time Frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months. ]
    RFS in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2). RFS is defined as the difference between date of randomization (which represents Day 0 for both arms) and the date of first recurrence (local, lymph node or distant organs, whichever comes first) or death.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first, assessed up to 72 months. ]
    OS in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2). OS is defined as the difference between date of randomization (which represents Day 0 for both arms) and the date of death.

  2. Recurrence free survival (RFS) as determined by the local investigator [ Time Frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months. ]
    RFS after randomization in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2). RFS is defined as the difference between date of randomization (which represents Day 0 for both arms) and the date of first recurrence (local, lymph node or distant organs, whichever comes first) or death.

  3. Pathological response (only for patients in Arm 1) [ Time Frame: Time Frame: Assessed at the time of surgical resection of the tumor lesions ]
    Categorization of pathological response as: p Complete Response, p near-Complete Response, p Partial Response, p None Response

  4. Percentage of Patients in Each Treatment Group with Adverse Events (AEs), AEs with CTCAE grade ≥3 [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the first follow-up visit (up to approximately 5 months). ]
  5. Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs) [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months). ]
  6. Number of patients with Drug-Induced Liver Injury (DILI) [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months). ]
  7. Number of patients with Adverse Events of Special Interest (AESI) [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months). ]
  8. Percentage of Subjects with Haematological/chemical Laboratory Abnormalities [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months). ]
  9. Percentage of participants with Electrocardiogram (ECG) and echocardiogram (ECHO) abnormality findings. [ Time Frame: 1) day 0-14 (screening) for both arm; 2) at week 5 (Safety assessment) only for arm 1. ]
    Data about QT/QTc intervals will be collected and analysed for QT/QTc prolongation potentially caused by treatment.

  10. Number of subjects with a clinically significant change from baseline in physical examination [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months) ]
  11. Number of subject with concomitant medication [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months) ]
  12. Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF [ Time Frame: 1) day 0-14 (screening) for arm 1; 2) at week 5 (Safety assessment) for Arm 1; 3) at week 12 (only first follow-up) for Arm 1. ]
  13. Number of subjects with a clinically significant change from baseline in vital signs (blood pressure) by visit [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months). ]
  14. Number of subjects with a clinically significant change from baseline in vital signs (heart rate) by visit [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months) ]
  15. Number of subjects with a clinically significant change from baseline in vital signs (body temperature) by visit [ Time Frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months) ]

Other Outcome Measures:
  1. Local recurrence-free survival (LRFS) [ Time Frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months ]
    LRFS after randomization in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2). LRFS is defined as survival free of loco-regional recurrence occurring at any time before systemic recurrence and other events are censored

  2. Distant metastasis-free survival (DMFS) [ Time Frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months ]
    DMFS after randomization in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2). DMFS is defined as survival free of systemic recurrence, including: 1) systemic recurrence outside the locoregional area at any time before or after loco-regional relapse, 2) systemic recurrence with or without loco-regional relapse, or 3) death from cancer with no information on systemic recurrence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of clinical stage IIIB and IIIC (AJCC v7) metastatic melanoma, eligible for complete surgical resection of all metastases (surgically resectable).
  2. Eligible subjects must have measurable disease and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (≥ 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm.
  3. Males or females, age ≥ 18 years
  4. ECOG Performance Status/WHO Performance Status ≤ 1
  5. Life expectancy of > 24 months
  6. Absolute neutrophil count > 1.5 x 109/L
  7. Hemoglobin > 9.0 g/dL
  8. Platelets > 100 x 109/L
  9. Total bilirubin ≤ 30 µmol/L (or ≤ 2.0 mg/dl)
  10. ALT and AST ≤ 2.5 x the upper limit of normal (ULN)
  11. Serum creatinine < 1.5 x ULN
  12. LDH serum level ≤ 1.5 x ULN
  13. Documented negative test for HIV, HBV and HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is also required.
  14. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) Grade ≤ 1 unless otherwise specified above
  15. All women of childbearing potential (WOCBP) must have negative pregnancy test results at the screening. WOCBP must be using, from the screening to three months following the last study drug administration, highly effective contraception methods. WOCBP and effective contraception methods are defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the safety visit (only WOCBP and only for patients in Arm 1).
  16. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  17. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  18. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Uveal melanoma or mucosal melanoma
  2. Evidence of distant metastases at screening
  3. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1), second primary melanoma in situ or any cancer curatively treated ≥ 5 years prior to study entry
  4. Concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  5. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  6. Inadequately controlled cardiac arrhythmias including atrial fibrillation
  7. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)
  8. LVEF ≤ 50% and/or abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator.
  9. Uncontrolled hypertension
  10. Ischemic peripheral vascular disease (Grade IIb-IV)
  11. Severe diabetic retinopathy
  12. Active autoimmune disease
  13. History of organ allograft or stem cell transplantation
  14. Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  15. Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies or any other constituent of the product.
  16. Breast feeding female
  17. Anti-tumor therapy (except small surgery) within 4 weeks before enrollment
  18. Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before enrollment
  19. Planned administration of growth factors or immunomodulatory agents within 7 days before enrollment
  20. Patient requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
  21. Any conditions that in the opinion of the investigator could hamper compliance with the study protocol
  22. Previous enrolment and randomization in the same study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567889


Contacts
Layout table for location contacts
Contact: Giuliano Elia +39057717816 regulatory@philogen.com
Contact: Serena Bettarini +39057717816 regulatory@philogen.com

Locations
Layout table for location information
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Principal Investigator: Jonathan S. Zager, MD FACS         
United States, New Jersey
Rutgers Cancer Institute, 195 Little Albany Street Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Roman Groisberg, MD    732-235-7356      
United States, Pennsylvania
St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd. Recruiting
Easton, Pennsylvania, United States, 18045
Contact: Sanjiv Agarwala, MD    484-503-4152    Linda.Hosler@sluhn.org   
Fox Chase Cancer Center 333 Cottman Avenue Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Jeffrey Farma, MD    215-728-4091      
Sponsors and Collaborators
Philogen S.p.A.
Investigators
Layout table for investigator information
Principal Investigator: Jonathan S Zager, MD FACS Moffitt Cancer Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Philogen S.p.A.
ClinicalTrials.gov Identifier: NCT03567889    
Other Study ID Numbers: PH-L19IL2TNF-01/18
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: September 18, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas